On June 4th, 2025, Blueprint Biomed was officially incorporated, marking the start of an ambitious journey in MedTech innovation and orthopedic solutions. As a spin-off from Charité – Universitätsmedizin Berlin, the company is dedicated to developing the next generation of bone implants that integrate scientific excellence, clinical insight, and practical applicability.

Blueprint Biomed was founded by Aarón Herrera, Janina Stadter, Felix Lorenz, Hans Leemhuis, Ansgar Petersen, and Georg Duda – a team combining expertise in biomedical research and medical technology entrepreneurship, united by the mission to improve patient outcomes in orthopedic care.

The company’s goal is to create clinically validated, science-driven implant solutions, develop adaptive technologies that support the natural bone healing process, and bridge the gap between cutting-edge research and everyday clinical practice. Following years of research, clinical input, and intensive preparation, Blueprint Biomed is now poised to bring its vision to life.

With this foundation, Blueprint Biomed aims to make a tangible impact on bone regeneration and orthopedic treatments for both patients and medical professionals. The company welcomes partnerships, pilot projects, and collaborations with organizations that share its commitment to transforming healthcare and advancing the future of bone healing.